{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:33:45Z","timestamp":1788798825343,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Otsuka Pharmaceutical Co. Ltd"},{"name":"Bristol Myers Squibb Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06135-7","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:07:47Z","timestamp":1734667667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Whole exome sequencing analysis of a patient with myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene"],"prefix":"10.1007","author":[{"given":"Rika","family":"Hosoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"6135_CR1","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-19.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"6135_CR2","doi-asserted-by":"crossref","unstructured":"Sakura T, Hayakawa F, Sugiura I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia. 2018;32(3):626\u2009\u2212\u200932.","DOI":"10.1038\/leu.2017.283"},{"key":"6135_CR3","doi-asserted-by":"crossref","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y, et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022;113(8):2763-77.","DOI":"10.1111\/cas.15427"},{"key":"6135_CR4","doi-asserted-by":"crossref","unstructured":"Tanaka H, Takeuchi M, Takeda Y, et al. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia. 2010;24(1):197\u2013200.","DOI":"10.1038\/leu.2009.167"},{"key":"6135_CR5","doi-asserted-by":"crossref","unstructured":"Telford N, Alexander S, McGinn OJ, et al. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6\u2013LYN gene fusion. Blood Cancer J. 2016;6(4):e412.","DOI":"10.1038\/bcj.2016.11"},{"key":"6135_CR6","doi-asserted-by":"crossref","unstructured":"Shvidel L, Sigler E, Vorst E, et al. A novel cytogenetic aberration found in stem cell leukemia\/lymphoma syndrome. Leukemia. 2008;22(3):644-6.","DOI":"10.1038\/sj.leu.2404942"},{"key":"6135_CR7","doi-asserted-by":"crossref","unstructured":"Ma ESK, Wan TSK, Au CH, et al. Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia. Cancer Genetics. 2017;218\u2013219:15\u2009\u2212\u20099.","DOI":"10.1016\/j.cancergen.2017.09.001"},{"key":"6135_CR8","unstructured":"Puente XS, Bea S, Valde\u00b4s-Mas R, et al. Non-coding recurent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519\u2009\u2212\u200924."},{"key":"6135_CR9","doi-asserted-by":"crossref","unstructured":"Zhang J, Lin X, Li Y, Zhang R. Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review. Onco Targets Ther. 2019;12:9085-92.","DOI":"10.2147\/OTT.S227122"},{"key":"6135_CR10","doi-asserted-by":"crossref","unstructured":"Eros Di G, Wayne W H, Claudio B. MEF2 and the tumorigenic process, hic sunt leones. Biochim Biophys Acta Rev Cancer. 2018;1870(2):261\u2009\u2212\u200973.","DOI":"10.1016\/j.bbcan.2018.05.007"},{"key":"6135_CR11","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28.","DOI":"10.1182\/blood.2022015850"},{"key":"6135_CR12","doi-asserted-by":"crossref","unstructured":"Todd W. Emerging themes in cohesin cancer biology. Nat Rev Cancer. 2020;20(9):504\u2009\u2212\u200915.","DOI":"10.1038\/s41568-020-0270-1"},{"key":"6135_CR13","doi-asserted-by":"crossref","unstructured":"Takeda Y, Nakaseko C, Tanaka H, et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol. 2011;153(5):589\u2009\u2212\u200998.","DOI":"10.1111\/j.1365-2141.2011.08663.x"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06135-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06135-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:14:52Z","timestamp":1739358892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06135-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":13,"alternative-id":["6135"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06135-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.F. received honoraria from Otsuka Pharmaceutical Co. Ltd. S.M. received honoraria from Bristol Myers Squibb Co., Ltd. K.K. received research funding and honoraria from Otsuka Pharmaceutical Co. Ltd. K.I. received research funding, consulting fees, and honoraria from Bristol Myers Squibb Co., Ltd. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Informed consent was obtained from the patient for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}